总收入 - 第二季度2024年总收入为1180万美元，较去年同期增长24%[2] - CVRx, INC. 2024年第二季度营收为11,807,000美元，同比增长24.5%[25] 美国心力衰竭业务 - 美国心力衰竭(HF)业务第二季度收入为1050万美元，较去年同期增长27%[3] - 美国HF业务的HF收入为1050万美元，较2023年同期的830万美元增长[6] 植入中心数量 - 美国活跃植入中心数量为189家，较2023年第二季度增长35%[3] 毛利润 - 毛利润为990万美元，较2023年同期增长24%[9] 费用 - 研发费用下降160万美元，为280万美元[10] - 销售和管理费用增加470万美元，为2110万美元[11] 净亏损 - 净亏损为1400万美元，每股亏损为0.65美元[13] - CVRx, INC. 2024年上半年净亏损为36,215,000美元，同比增长57.6%[25] 现金及现金等价物 - 公司现金及现金等价物为7040万美元[14] 预测 - 公司全年2024年预计总收入在5000万至5300万美元之间[16]

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. Recent Highlights Total revenue for the second quarter 2024 was $11.8 million, an increase of 24% over the prior year quarterU.S. Heart Failure (HF) revenue for the s ...

MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm Ea ...

MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm E ...

CVRx (CVRX) shares ended the last trading session 19% higher at $8.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 30.1% loss over the past four weeks.CVRx stock rallied following the company’s announcement to appoint Robert John as Chief Revenue Officer effective June 27. CVRx management expects John’s presence will help the company to expand the adoption of Barostim therapy.This medical device company is expe ...

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive ...

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive ...

CVRx (CVRX) shares rallied 33.9% in the last trading session to close at $8.69. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 19.9% loss over the past four weeks.CVRx scored a strong price increase driven by the optimism surrounding the company’s recent presentation at William Blair 44rd Annual Growth Stock Conference held on Jun 5, 2024. The company drew attention to the massive $2.2 billion U.S. annual ne ...

MINNEAPOLIS, May 22, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024. The Company is scheduled to present at 8:40am Central Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, In ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether CVRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action] On April 30, 2024, CVRx issued a press ...